Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma.

IF 2.5 4区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

World Journal of Gastrointestinal Oncology Pub Date : 2024-08-15 DOI:10.4251/wjgo.v16.i8.3481

Meng-Xuan Zuo, Chao An, Yu-Zhe Cao, Jia-Yu Pan, Lu-Ping Xie, Xin-Jing Yang, Wang Li, Pei-Hong Wu

{"title":"Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma.","authors":"Meng-Xuan Zuo, Chao An, Yu-Zhe Cao, Jia-Yu Pan, Lu-Ping Xie, Xin-Jing Yang, Wang Li, Pei-Hong Wu","doi":"10.4251/wjgo.v16.i8.3481","DOIUrl":null,"url":null,"abstract":"Background: Hepatic arterial infusion chemotherapy and camrelizumab plus apatinib (TRIPLET protocol) is promising for advanced hepatocellular carcinoma (Ad-HCC). However, the usefulness of microwave ablation (MWA) after TRIPLET is still controversial.Aim: To compare the efficacy and safety of TRIPLET alone (T-A) vs TRIPLET-MWA (T-M) for Ad-HCC.Methods: From January 2018 to March 2022, 217 Ad-HCC patients were retrospectively enrolled. Among them, 122 were included in the T-A group, and 95 were included in the T-M group. A propensity score matching (PSM) was applied to balance bias. Overall survival (OS) was compared using the Kaplan-Meier curve with the log-rank test. The overall objective response rate (ORR) and major complications were also assessed.Results: After PSM, 82 patients were included both the T-A group and the T-M group. The ORR (85.4%) in the T-M group was significantly higher than that (65.9%) in the T-A group (P < 0.001). The cumulative 1-, 2-, and 3-year OS rates were 98.7%, 93.4%, and 82.0% in the T-M group and 85.1%, 63.1%, and 55.0% in the T-A group (hazard ratio = 0.22; 95% confidence interval: 0.10-0.49; P < 0.001). The incidence of major complications was 4.9% (6/122) in the T-A group and 5.3% (5/95) in the T-M group, which were not significantly different (P = 1.000).Conclusion: T-M can provide better survival outcomes and comparable safety for Ad-HCC than T-A.","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334027/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v16.i8.3481","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatic arterial infusion chemotherapy and camrelizumab plus apatinib (TRIPLET protocol) is promising for advanced hepatocellular carcinoma (Ad-HCC). However, the usefulness of microwave ablation (MWA) after TRIPLET is still controversial.

Aim: To compare the efficacy and safety of TRIPLET alone (T-A) vs TRIPLET-MWA (T-M) for Ad-HCC.

Methods: From January 2018 to March 2022, 217 Ad-HCC patients were retrospectively enrolled. Among them, 122 were included in the T-A group, and 95 were included in the T-M group. A propensity score matching (PSM) was applied to balance bias. Overall survival (OS) was compared using the Kaplan-Meier curve with the log-rank test. The overall objective response rate (ORR) and major complications were also assessed.

Results: After PSM, 82 patients were included both the T-A group and the T-M group. The ORR (85.4%) in the T-M group was significantly higher than that (65.9%) in the T-A group (P < 0.001). The cumulative 1-, 2-, and 3-year OS rates were 98.7%, 93.4%, and 82.0% in the T-M group and 85.1%, 63.1%, and 55.0% in the T-A group (hazard ratio = 0.22; 95% confidence interval: 0.10-0.49; P < 0.001). The incidence of major complications was 4.9% (6/122) in the T-A group and 5.3% (5/95) in the T-M group, which were not significantly different (P = 1.000).

Conclusion: T-M can provide better survival outcomes and comparable safety for Ad-HCC than T-A.

查看原文本刊更多论文

卡瑞珠单抗、阿帕替尼和肝动脉灌注化疗联合微波消融治疗晚期肝细胞癌。

背景：肝动脉灌注化疗和坎瑞珠单抗加阿帕替尼（TRIPLET方案）对晚期肝细胞癌（Ad-HCC）有很好的疗效。然而，TRIPLET后的微波消融（MWA）是否有用仍存在争议。目的：比较单独TRIPLET（T-A）与TRIPLET-MWA（T-M）治疗Ad-HCC的疗效和安全性：方法：2018年1月至2022年3月，回顾性纳入217例Ad-HCC患者。其中，122人被纳入T-A组，95人被纳入T-M组。采用倾向评分匹配法（PSM）平衡偏倚。采用 Kaplan-Meier 曲线和对数秩检验比较总生存期（OS）。此外，还对总体客观反应率（ORR）和主要并发症进行了评估：PSM 后，T-A 组和 T-M 组共纳入 82 例患者。T-M组的ORR（85.4%）明显高于T-A组（65.9%）（P < 0.001）。T-M组的1年、2年和3年累积OS率分别为98.7%、93.4%和82.0%，T-A组分别为85.1%、63.1%和55.0%（危险比=0.22；95%置信区间：0.10-0.49；P<0.001）。T-A组主要并发症的发生率为4.9%（6/122），T-M组为5.3%（5/95），两者无显著差异（P = 1.000）：结论：与T-A相比，T-M能为Ad-HCC提供更好的生存结果和相当的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Gastrointestinal Oncology Medicine-Gastroenterology

CiteScore

4.20

自引率

3.30%

发文量

1082

期刊介绍： The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.